The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers

The adjuvant and post-surgical treatment of gynaecological cancers has historically been guided by the estimation of relapse risk based on clinicopathological factors determined at the time of cancer diagnosis. The recent advancement of genomic and molecular characterisation of gynaecological cancer...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical obstetrics & gynaecology 2022-01, Vol.78, p.14-35
Main Authors: Wijaya, Silvana Talisa, Ngoi, Natalie YL, Tan, David SP
Format: Article
Language:English
Subjects:
Biomarkers
Cancer therapy
Carcinoma, Ovarian Epithelial
Endometrial Neoplasms - genetics
Endometrial Neoplasms - surgery
Female
Genital Neoplasms, Female - genetics
Genital Neoplasms, Female - surgery
Gynaecological cancers
Humans
Molecular assays
Neoplasm Recurrence, Local
Ovarian Neoplasms - genetics
Ovarian Neoplasms - surgery
Uterine Cervical Neoplasms
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The adjuvant and post-surgical treatment of gynaecological cancers has historically been guided by the estimation of relapse risk based on clinicopathological factors determined at the time of cancer diagnosis. The recent advancement of genomic and molecular characterisation of gynaecological cancers has begun to shift paradigms in the selection of adjuvant treatment strategy. Recent data regarding the predictive and/or prognostic value of molecular tests in the treatment of advanced ovarian cancer as well as early stage endometrial cancer have been the first such examples to enter adjuvant treatment guidelines for these diseases. In this article, we discuss the current state and future development of molecular assays for gynaecological cancers and how they impact upon treatment selection for ovarian, endometrial and cervical cancers in the post-surgical setting. •Molecular biomarkers have an increasing role in the selection of adjuvant treatment.•Homologous recombination deficiency (HRD) predicts benefit from maintenance poly(ADP)-ribose polymerase inhibitor (PARPi) in advanced ovarian cancer.•Endometrial cancer (EC) molecular subgroups have prognostic and predictive significance. Trials are ongoing to validate the role of molecular biomarkers prospectively.•POLE-mutant ECs have an excellent prognosis and may not benefit from adjuvant therapy.•p53-mutant ECs derive the most benefit from the addition of chemotherapy to radiation therapy.
ISSN:1521-6934
1532-1932
DOI:10.1016/j.bpobgyn.2021.06.003